⌘K
t
Cambridge Cognition Holdings plc announced that Rob Baker (Group Chief Operating Officer and Senior Executive Director) and Ronald Openshaw (Chief Financial Officer and Head of Corporate Development) will deliver a live investor presentation. This presentation, relating to the Interim Results, is scheduled for 03 September 2025 at 11:00 BST via Investor Meet Company. Existing and potential shareholders can submit questions pre-event until 02 September 2025 at 09:00 BST.
01 September 2025
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Investor Presentation via Investor Meet Company
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce that Rob Baker (Group Chief Operating Officer and Senior Executive Director) and Ronald Openshaw (Chief Financial Officer and Head of Corporate Development) will provide a live presentation relating to the Interim Results via Investor Meet Company on 03 September 2025, 11:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 02 September 2025, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Cambridge Cognition Holdings plc via:
https://www.investormeetcompany.com/cambridge-cognition-holdings-plc/register-investor
Investors who already follow Cambridge Cognition Holdings plc on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.
Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:
· Clinical Studies for new pharmaceuticals;
· Academic Research for scientists to understand CNS disorders;
· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.
For further information, visit: www.cambridgecognition.com
END